Our Viral Sensitizer technology consists of a library of over one hundred small molecules that can safely overcome the natural immunological defences in the human and animal body that suppress effective viral medicines.
When immune responses are safely reduced, targeted infection by medicinal viruses can improve. This has a number of practical and sought-out applications that positively contribute to public health goals and better clinical care.
We first identified our novel Viral Sensitizers by employing an innovative high-throughput screening process. Virica continues to employ this cutting-edge equipment and can identify the most synergistic Viral Sensitizer molecules from our library for any virus strain.
We can tailor formulations of our Viral Sensitizers to boost virus yield in your manufacturing facility or improve the effects of your viral therapies.
Location: Canada, Ontario, (Old) Ottawa
Employees: 11-50
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Capital An... | capitalang... |
Mentions in press and media 3
| Date | Title | Description | Source |
| 24.05.2023 | Viral Vector Manufacturing — Are Antiviral Defenses the Miss... | The growing interest in unraveling viral vector quality metrics beyond yield increase via raw titers... | prweb.com/... |
| 27.10.2022 | Process Intensification in AAV Gene Therapy, Upcoming Webina... | One of the major bottlenecks, addressed in this webinar, is the problem of low manufacturing yield. ... | prweb.com/... |
| - | Virica Biotech | “Viral Sensitizers (VSE) for drug developers and manufacturers are small molecules that improve vira... | fastfounde... |